Lonza to make antibody-drug conjugates for a major client

Lonza has extended its antibody-drug conjugate (ADC) manufacturing contract with a major biopharmaceutical customer, according to a press statement, which does not name the client. Lonza says that as part of the agreement it will build an 800 m² bioconjugation suite at its complex in Visp, Switzerland, to manufacture ADCs for “hard-to-treat cancers.” The Swiss drug services firm says it expects the facility to open in 2027 and to generate about 100 new jobs.